Table 8.
Outcome measures of five studies
| Analysis | Black, 2007 | Winblad, 2006 | Feldman, 2005 | Homma, 2008 | Ferris, 2013 | ||||
|---|---|---|---|---|---|---|---|---|---|
| LOCF | OC | LOCF | MMRM | OC | LOCF | LOCF | LOCF | ||
| Donepezil dose | 10 mg | 10 mg | 10 mg | 10 mg | 10 mg | 10 mg | 5 mg | 10 mg | 23 mg |
| SIB LS mean differencea (score (p)) | 5.32 (0.0001) | 5.59 (0.0008) | 5.6 (0.008) | 4.5 (0.01) | 5.8 (0.008) | 7.42 (0.0017) | 6.7 (0.001) | 8.9 (0.001) | MMSE 0‐5 = 6.048 MMSE 6‐10 = 3.258 |
| MMSE LS mean difference (score (p)) | 0.68 (0.0267) | 0.74 (0.0409) | 1.4 (0.009) | 1.0 (0.01) | 1.4 (0.009) | 1.00 (0.0022) | — | — | — |
LS, least squares.
a
LS mean treatment difference between placebo and donepezil treatment groups, except for Ferris et al,35 who compared 10 mg with 23 mg donepezil.